Home » Topics » Regulatory » EMA

EMA
RSS

Avastin recommended for approval of recurrent, platinum-sensitive ovarian cancer in Europe

Sep. 26, 2012

Novartis obtains positive CHMP opinions for Galvus and Eucreas

Sep. 26, 2012

CHMP gives positive opinion on Cialis in new indication

Sep. 26, 2012

CHMP recommends VEGF Trap-Eye in wet AMD

Sep. 26, 2012

CHMP recommends expanded approval of Trajenta tablets

Sep. 25, 2012

CHMP recommends Constella in IBS-C

Sep. 25, 2012

EMA committee recommends approval of new apixaban indication

Sep. 25, 2012

Biovest provides update on planned MAA for NHL vaccine candidate

Sep. 21, 2012

RepliGen withdraws MAA for SecreFlo

Sep. 17, 2012

PM-01183 receives positive opinion for orphan drug status in E.U.

Sep. 10, 2012

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...